Inhaled corticosteroid and long-acting beta2-adrenergic receptor agonist combination

This page covers all Inhaled corticosteroid and long-acting beta2-adrenergic receptor agonist combination drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Beta2-adrenergic receptor.

Targets

Beta2-adrenergic receptor

Phase 3 pipeline (1)

• Symbicort Turbuhaler · Orion Corporation, Orion Pharma · Respiratory
  Symbicort Turbuhaler is a combination of budesonide, an inhaled corticosteroid, and formoterol, a long-acting beta2-adrenergic receptor agonist, used to control symptoms of asthma and chronic obstructive pulmonary disease (COPD).